TG Therapeutics (OTCMKTS:TGTX) Announces Earnings Results

TG Therapeutics (OTCMKTS:TGTX) announced its quarterly earnings data on Monday. The company reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $2.22, RTT News reports. During the same quarter last year, the company earned $0.02 EPS.

TG Therapeutics Stock Down 0.4%

TG Therapeutics stock traded down $0.15 during trading hours on Wednesday, reaching $33.66. 78,003 shares of the stock were exchanged, compared to its average volume of 2,353,573. The company has a market capitalization of $5.34 billion, a price-to-earnings ratio of 90.97 and a beta of 1.97. TG Therapeutics has a twelve month low of $25.28 and a twelve month high of $46.48.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.